NP-MP1 – NanoPhoria bioscience

12 November 2025

NP-MP1

Search

Recent Posts

NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform
NanoPhoria Bioscience Awarded €17.5 M From European Innovation Council’s Accelerator Program
NanoPhoria appoints Dr Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of the Board of Directors
NanoPhoria Bioscience publishes groundbreaking study in major cardiology journal
Alessio Alogna, one of the founders of NanoPhoria, presented our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event, which was held this year in Chicago (AHA 2022)